MetaVia (MTVA) Competitors $1.56 -0.03 (-1.89%) As of 03/27/2025 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock MTVA vs. FBRX, ONCY, OCX, IMRX, KRON, VNRX, CELU, IMMX, CTOR, and PDSBShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Forte Biosciences (FBRX), Oncolytics Biotech (ONCY), OncoCyte (OCX), Immuneering (IMRX), Kronos Bio (KRON), VolitionRx (VNRX), Celularity (CELU), Immix Biopharma (IMMX), Citius Oncology (CTOR), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Forte Biosciences Oncolytics Biotech OncoCyte Immuneering Kronos Bio VolitionRx Celularity Immix Biopharma Citius Oncology PDS Biotechnology MetaVia (NASDAQ:MTVA) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk. Which has more risk and volatility, MTVA or FBRX? MetaVia has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Does the media favor MTVA or FBRX? In the previous week, MetaVia had 8 more articles in the media than Forte Biosciences. MarketBeat recorded 9 mentions for MetaVia and 1 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 0.84 beat MetaVia's score of 0.75 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Overall Sentiment MetaVia Positive Forte Biosciences Positive Do insiders and institutionals have more ownership in MTVA or FBRX? 1.4% of MetaVia shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 1.1% of MetaVia shares are held by company insiders. Comparatively, 3.1% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is MTVA or FBRX more profitable? Forte Biosciences' return on equity of -151.43% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -189.12% -122.31% Forte Biosciences N/A -151.43%-118.92% Does the MarketBeat Community believe in MTVA or FBRX? Forte Biosciences received 28 more outperform votes than MetaVia when rated by MarketBeat users. However, 100.00% of users gave MetaVia an outperform vote while only 61.22% of users gave Forte Biosciences an outperform vote. CompanyUnderperformOutperformMetaViaOutperform Votes2100.00% Underperform VotesNo VotesForte BiosciencesOutperform Votes3061.22% Underperform Votes1938.78% Do analysts prefer MTVA or FBRX? MetaVia currently has a consensus target price of $12.00, indicating a potential upside of 669.23%. Forte Biosciences has a consensus target price of $23.58, indicating a potential upside of 198.15%. Given MetaVia's higher possible upside, equities research analysts clearly believe MetaVia is more favorable than Forte Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, MTVA or FBRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$12.47MN/AN/AForte BiosciencesN/AN/A-$31.48M-$16.29-0.49 SummaryForte Biosciences beats MetaVia on 8 of the 12 factors compared between the two stocks. Remove Ads Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.50M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.02%P/E RatioN/A7.2023.1319.03Price / SalesN/A226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.456.476.944.33Net Income-$12.47M$141.90M$3.20B$247.06M7 Day Performance0.65%-3.05%-2.30%-0.52%1 Month Performance6.85%-4.63%3.10%-3.73%1 Year PerformanceN/A-8.61%11.22%1.74% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.0067 of 5 stars$1.56-1.9%$12.00+669.2%N/A$13.50MN/A0.0010FBRXForte Biosciences3.0307 of 5 stars$8.51+34.7%$23.58+177.1%+28,357.3%$54.40MN/A-0.525ONCYOncolytics Biotech2.0114 of 5 stars$0.63+0.9%$4.00+530.2%-40.4%$54.27MN/A-2.3530Positive NewsOCXOncoCyte2.5386 of 5 stars$3.04-8.7%$4.42+45.3%+8.1%$53.06M$709,000.000.00120Earnings ReportAnalyst ForecastShort Interest ↑IMRXImmuneering3.2961 of 5 stars$1.69-2.9%$11.00+550.9%-31.7%$52.47M$320,000.00-0.8660Short Interest ↓Analyst RevisionKRONKronos Bio3.657 of 5 stars$0.85-1.6%$1.63+90.5%-33.5%$51.99M$9.85M-0.60100Short Interest ↓VNRXVolitionRx1.8224 of 5 stars$0.55+0.9%$3.75+578.2%-27.7%$51.23M$1.29M-1.5480News CoverageGap UpCELUCelularity0.3322 of 5 stars$2.15+15.0%N/A-61.9%$51.19M$48.20M0.00220Short Interest ↑IMMXImmix Biopharma2.717 of 5 stars$1.85+1.6%$7.00+278.4%-44.3%$50.89MN/A-2.189Earnings ReportNews CoveragePositive NewsCTORCitius OncologyN/A$0.79+11.8%$3.00+277.8%N/A$50.80MN/A0.00N/ANews CoveragePositive NewsGap UpPDSBPDS Biotechnology1.7655 of 5 stars$1.32-3.6%$11.67+783.8%-67.5%$50.42MN/A-1.1420Earnings ReportAnalyst ForecastShort Interest ↓News Coverage Remove Ads Related Companies and Tools Related Companies FBRX Alternatives ONCY Alternatives OCX Alternatives IMRX Alternatives KRON Alternatives VNRX Alternatives CELU Alternatives IMMX Alternatives CTOR Alternatives PDSB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MTVA Stock Free MTVA Stock Alerts